<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208194</url>
  </required_header>
  <id_info>
    <org_study_id>MGN1703-C02</org_study_id>
    <secondary_id>2009-017432-40</secondary_id>
    <nct_id>NCT01208194</nct_id>
  </id_info>
  <brief_title>Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma With Disease Control After Initial First-line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mologen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mologen AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, randomized, double-blind, multi-center clinical study to evaluate efficacy&#xD;
      and safety of a maintenance therapy with the immunomodulator MGN1703 compared to placebo&#xD;
      control. The study will be conducted in patients with advanced colorectal carcinoma (AJCC&#xD;
      Stage IV) with disease control after first-line standard chemotherapy regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The phase 2 study will be conducted in patients with advanced colorectal carcinoma with&#xD;
      disease control after first-line standard chemotherapy regimens with oral or intravenous&#xD;
      fluoropyrimidines/leucovorin and irinotecan or oxaliplatin combined with a standard dose of&#xD;
      bevacizumab lasted between 4.5 and 6 months, whereas the treatment duration with irinotecan&#xD;
      or oxaliplatin should not be less than 3 months. Studies confirmed that completely&#xD;
      chemotherapy-free intervals can be applicable in patients with advanced colorectal carcinoma&#xD;
      who achieved disease control after initial first-line chemotherapy. Those therapy holidays&#xD;
      minimize toxicity and unnecessary treatment load, reduce intensity of treatment, allow&#xD;
      patients to stay longer on therapy, prevent therapy discontinuations due to toxicity,&#xD;
      preserve the ability to re-administer chemotherapy later, and increase quality of life of the&#xD;
      patients. The therapy-free interval represents a possibility to evaluate the efficacy of the&#xD;
      study drug, MGN1703.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of median progression-free survival (PFS) in both treatment groups</measure>
    <time_frame>Measured on accrual time 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PFS rate</measure>
    <time_frame>Measured at landmarks 12, 18 and 24 weeks after treatment start, and afterwards every 6 weeks until treatment stop</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of median overall survival (OS)</measure>
    <time_frame>Measured on accrual time 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of OS proportion in both groups</measure>
    <time_frame>Measured at landmarks 12, 18 and 24 weeks after treatment start, and afterwards every 6 weeks until treatment stop</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of overall response rate (ORR)</measure>
    <time_frame>Measured on accrual time 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of duration of response (complete response, partial response, stable disease) as time from initial determination of response to progressive disease measured by RECIST</measure>
    <time_frame>Measured on accrual time 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the dynamic of clinical and laboratory parameters</measure>
    <time_frame>An average time: participants are followed until progress</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunologic response to MGN1703</measure>
    <time_frame>An average time: participants are followed until progress</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life (QOL)</measure>
    <time_frame>An average time: participants are followed until progress</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety profile of MGN1703</measure>
    <time_frame>An average time: participants are followed until progress</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Advanced Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>MGN1703</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGN1703</intervention_name>
    <description>solution, 60 mg, twice a week, until progression</description>
    <arm_group_label>MGN1703</arm_group_label>
    <other_name>immunomodulator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>solution, 60 mg, twice a week, until progression</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects older than 18 years of age&#xD;
&#xD;
          -  Histologically confirmed colorectal carcinoma&#xD;
&#xD;
          -  Radiological confirmation of unresectable advanced colorectal carcinoma (AJCC Stage&#xD;
             IV) prior to start of initial first-line therapy&#xD;
&#xD;
          -  At least one measurable lesion according to RECIST measured within 2 weeks prior to&#xD;
             treatment start in case of partial response or stable disease&#xD;
&#xD;
          -  Prior initial first-line therapy included oral or intravenous&#xD;
             fluoropyrimidines/leucovorin,irinotecan or oxaliplatin with or without a standard dose&#xD;
             of bevacizumab lasted between 4.5 and 6 months and finished (last day of last cycle)&#xD;
             within 2 weeks prior to treatment start (treatment duration with irinotecan or&#xD;
             oxaliplatin should not be less than 3 months)&#xD;
&#xD;
          -  Patients who achieved disease control measured as objective response or disease&#xD;
             stabilization after initial first-line therapy&#xD;
&#xD;
          -  No curative standard therapy is available for the patient after first-line treatment&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Adequate organ function, hemoglobin ≥ 9 g/L, white blood cell count (WBC) ≥ 3.0 x&#xD;
             109/L, absolute neutrophil count ≥ 1.5 x 109/L, platelets &gt; 100 x109/L, aspartate and&#xD;
             alanine aminotransferase (AST and ALT) ≤ 2.5 x ULN, bilirubin &lt; 1.5 x ULN, blood&#xD;
             creatinine ≤ 1.5 X ULN, prothrombin time (PT) and activated thromboplastin time (aPTT)&#xD;
             within normal range&#xD;
&#xD;
          -  Negative pregnancy test in women with childbearing potential&#xD;
&#xD;
          -  Expected adequacy of follow-up&#xD;
&#xD;
          -  Signed informed consent form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than one line of systemic chemotherapy for metastatic colorectal carcinoma&#xD;
&#xD;
          -  Tumor progression after initial first-line therapy&#xD;
&#xD;
          -  Clinically significant concomitant diseases or conditions, which in opinion of the&#xD;
             investigator would lead to an unacceptable risk for the subject to participate in the&#xD;
             study&#xD;
&#xD;
          -  Prior or current other malignancy, except adequately treated superficial bladder&#xD;
             cancer, basal or squamous cell carcinoma of the skin or other cancer for which the&#xD;
             subject has been disease free for more than 3 years&#xD;
&#xD;
          -  Known central nervous system metastases&#xD;
&#xD;
          -  Active or uncontrolled infections&#xD;
&#xD;
          -  Transfusion-dependent anemia&#xD;
&#xD;
          -  History of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  Known hypersensitivity to oligonucleotides or excipients of the formulation&#xD;
&#xD;
          -  Pregnancy and/or nursing&#xD;
&#xD;
          -  Concurrent chronic systemic immune therapy or immunosuppressant medication, including&#xD;
             steroid treatment&#xD;
&#xD;
          -  Concurrent chemotherapy, hormonal therapy (except hormonal contraception and hormonal&#xD;
             replacement therapy for menopausal women), or immunotherapy within the last 2 weeks&#xD;
             prior to randomization or during the conduct of the study - Concurrent radiotherapy&#xD;
             within the last 6 months prior to randomization or during the conduct of the study&#xD;
&#xD;
          -  Known HIV seropositivity or active hepatitis B or C infection&#xD;
&#xD;
          -  Planned major surgery during the study&#xD;
&#xD;
          -  Participation in another clinical study with other investigational drugs within 30&#xD;
             days prior to the first treatment day&#xD;
&#xD;
          -  Vaccination within 3 months prior to the first treatment day&#xD;
&#xD;
          -  Any medical, mental, psychological or psychiatric condition which in opinion of the&#xD;
             investigator would not permit the subject to complete the study or understand the&#xD;
             patient information&#xD;
&#xD;
          -  Presence of drug and/or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Joachim Schmoll</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Innere Medizin IV, Universitätsklinikum Halle (Saale)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Innere Medizin I, Abteilung für Klinische Onkologie, Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Clinic, Faculty Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Cancérologie Digestive, Institut de Cancérologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologischer Schwerpunkt am Oskar-Helene-Heim</name>
      <address>
        <city>Berlin</city>
        <zip>14195</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin IV, Onkologie/ Hämatologie/ Hämostaseologie, Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kath. Marienkrankenhaus GmbH, Allgemeine Onkologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22087</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin, Klinik für Hämatologie, Onkologie, Immunologie, Universitätsklinikum Giessen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik, Abteilung für Onkologie, Hämatologie Immunologie, Rheumatologie und Pulmologie Universität Tübingen, Immuntherapie, Station 65 Med. Klinik Abt. II</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Russian Scientific Oncology Center named after N.N. Blokhin RAMN&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-state health care institution &quot;Central Clinical Hospital No. 2 named after N.A. Semashko OAO &quot;RZHD&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>August 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <last_update_submitted>June 19, 2014</last_update_submitted>
  <last_update_submitted_qc>June 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced colorectal carcinoma</keyword>
  <keyword>Maintenance therapy</keyword>
  <keyword>Immunomodulator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

